Review

Current Endoscopic Management of Malignant Biliary Stricture

Chi-Chih Wang 1,2,3, Tzu-Wei Yang 2,3,4, Wen-Wei Sung 1,2,5 and Ming-Chang Tsai 1,2,3,*

1 Institute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan; bananaudwang@gmail.com (C.-C.W.); flutewayne@gmail.com (W.-W.S.)
2 School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan; joviyoung@gmail.com
3 Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung 40201, Taiwan
4 Institute and Department of Biological Science and Technology, National Chiao Tung University, Hsinchu 30010, Taiwan
5 Department of Urology, Chung Shan Medical University Hospital, Taichung 40201, Taiwan
* Correspondence: tmc1110@yahoo.com.tw

Received: 21 December 2019; Accepted: 2 March 2020; Published: 5 March 2020

Abstract: Biliary and pancreatic cancers occur silently in the initial stage and become unresectable within a short time. When these diseases become symptomatic, biliary obstruction, either with or without infection, occurs frequently due to the anatomy associated with these cancers. The endoscopic management of these patients has changed, both with time and with improvements in medical devices. In this review, we present updated and integrated concepts for the endoscopic management of malignant biliary stricture. Endoscopic biliary drainage had been indicated in malignant biliary obstruction, but the concept of endoscopic management has changed with time. Although routine endoscopic stenting should not be performed in resectable malignant distal biliary obstruction (MDBO) patients, endoscopic biliary drainage is the treatment of choice for palliation in unresectable MDBO patients. Self-expanding metal stents (SEMS) have better stent patency and lower costs compared with plastic stents (PS). For malignant hilum obstruction, PS and uncovered SEMS yield similar short-term outcomes, while a covered stent is not usually used due to a potential unintentional obstruction of contralateral ducts.

Keywords: endoscopic management; malignancy; biliary stricture

1. Introduction

Percutaneous transhepatic biliary drainage was introduced ~40 years ago [1] for the treatment of obstructive jaundice; however, the more convenient endoscopic trans-papillary drainage, which was introduced in 1981 [2,3], is more commonly used in clinical practice today. The most common malignancy diseases that can cause obstructive jaundice are cholangiocarcinoma, pancreatic cancer [4], and ampullary neoplasms. Cholangiocarcinoma, which arises from the epithelial cells of the intrahepatic or extrahepatic bile ducts, can be divided into intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC). The incidence of ECC has increased in the USA [5], whereas ICC incidence has increased in both sexes in Europe [6]. At the same time, the pancreatic cancer burden has also increased in recent years [7], making endoscopic management of malignant obstructive jaundice an important issue. Due to the lack of effective treatment choice, the need for endoscopic/radiologic approaches has increased and the clinical condition may have changed due to emerging evidence in targeted therapies of cholangiocarcinoma in the following years [8].
Differences in the level of obstruction of the biliary system allow for a further division of these kinds of problems into resectable or unresectable hilum or distal biliary obstructions. Computed tomography (CT), magnetic resonance imaging (MRI), magnetic resonance cholangiopancreatography (MRCP), and even endoscopic ultrasound sonography (EUS) should be used to evaluate the stage and primary source of a malignancy [9,10].

2. Resectable Malignancy

Treatment plans for malignancies with different primary origins differ from one another when resectable biliary obstructive malignancy diseases are discussed. In general, routine endoscopic stenting has no obvious clinical benefits for patients with malignant distal biliary obstruction (MDBO) [11–14]. Nevertheless, most endoscopists worldwide still perform routine endoscopic retrograde cholangiopancreatography (ERCP) and even biliary stenting prior to surgical approaches.

For cholangiocarcinoma, the Bismuth classifications (Figure 1) have been used for decades as a treatment guide [15]. ERCP is useful for confirmation of the obstruction level and for histological proof via either brushing cytology or biopsy, although these have limited sensitivity [16,17]. Mother–baby cholangioscopy [18–20] and single-operator SpyGlass cholangioscopy [21] plus targeted biopsy can improve the sensitivity for detecting a biliary malignancy to 89–100% and 66.2% and the specificity to 87–96% and 97.0%, respectively. For Bismuth type I lesions without lymph node and distant metastasis, surgical resection should be considered a first approach.

For hilum cholangiocarcinoma without distant metastasis, resectable tumors present the possibility of resection of the involved intra- and extrahepatic bile ducts as well as the associated hepatic lobes and caudate lobe. Some recent reports have shown excellent results after surgical resection in patients with Bismuth III and IV disease [22,23], but the surgical management of these patients is still under debate.

Endoscopic stenting is the mainstream endoscopic management approach for malignant distal biliary obstruction of cholangiocarcinoma or pancreatic cancers, but most clinical studies [11,24] and meta-analyses [12–14] have failed to show any benefits of routine pre-operative endoscopic stenting in MDBO patients. However, although this stenting should be avoided in resectable MDBO, an interesting study showed that more than 80% of doctors in academic centers in the USA still perform this drainage prior to surgery [25]. In pancreatic cancer patients with asymptomatic obstructive jaundice, the recommendation of the Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE) is against routine preoperative ERCP [9].

In ampullary neoplasms, EUS and intraductal ultrasound sonography (IDUS) can assess the depth of invasion as well as the intraductal extension. Importantly, surgical ampullectomy can reduce medical expenses yet have similar clinical outcomes for those that are achieved via pancreaticoduodenectomy [26] for ampullary neoplasms that are limited to the ampulla of Vater. Endoscopic ampullectomy [27] can be performed for adenoma and early ampullary adenocarcinoma by experienced endoscopists in well-equipped endoscopy centers.
3. Unresectable Malignancy

3.1. Malignant Distal Biliary Obstruction

Endoscopic biliary drainage with biliary stent placement is the treatment of choice for palliation in patients with distal malignant biliary obstruction that is caused by unresectable neoplasms, with a success rate of up to 95% [28–30] and with a lower morbidity compared to surgery [31]. Endoscopic drainage has a low risk of complications, but it is associated with a high probability of recurrent biliary obstruction [32] when compared with surgical bypass. After an endobiliary radiofrequency ablation (RFA) system was applied to biliary malignant obstructions, series intraluminal RFA and self-expanding metal stents (SEMS) became a safe treatment choice with better intervention-free survival compared to SEMS alone [33–35]. Percutaneous trans-hepatic cholangiography and drainage (PTCD) should be reserved for unsuccessful endoscopic procedures in patients with MDBO.

In some situations, PTCD has been used as part of a rendezvous endoscopic approach. A comparison in 2016 between EUS-guided and PTCD rendezvous drainage after the failure of primary ERCP in MDBO showed that EUS rendezvous had a significantly lower success rate than the PTCD rendezvous [36]. However, successful EUS rendezvous offered a significantly shorter post-procedure hospital stay and fewer follow-up biliary interventions. As technology improves and skills in EUS-guided biliary drainage gradually mature, EUS-guided biliary drainage will produce better outcomes than that of conventional ERCP biliary drainage in high-tech endoscopy centers [37–39].

3.2. Stent Selection

Different stent types are available for the treatment of MDBO. SEMS (Figure 2) have a larger luminal diameter than plastic stents (Figure 3), and they were designed to overcome the limitations of occlusion and stent patency that are associated with plastic stents [40]. SEMS offer a better stent patency of 3.6–9.1 months compared to 1.8–5.5 months for plastic stents [41–44] in MDBO, but the median patient survival times are similar with either stent type [45]. SEMS are more expensive than plastic stents, but SEMS lower the total medical expenses [41,46] due to the reduced frequency of re-interventions. Different types of metal stents are now available, and covered stents show superior stent patency over uncovered metal stents in the treatment of MDBO [47]. Some previous case studies showed no significant differences in stent patency between covered and uncovered SEMS because covered stents had more drawbacks due either to stent migration or the occurrence of acute cholecystitis [48–50]. Recent studies have revealed that fully covered SEMS (FCSEMS) that are used for MDBO treatment have low stent migration rates and trigger few cholecystitis events [51]. A prospective study of unresectable pancreatic cancer with obstructive jaundice demonstrated a significantly longer survival time and no stent dysfunction for covered SEMS with an anti-migration
system than it did without an anti-migration system [52,53]. These studies suggest that covered SEMS are a valuable and cost-effective option for MDBO treatment because of their increased patency, less tumor in-growth, and easy removal [53,54]. However, several recent large studies [55–57] and a recent meta-analysis from Canada [58] have revealed no clear benefit of FCSEMS over uncovered SEMS (UCSEMS) in terms of stent patency and complications. Conversely, one multi-center study from Italy showed increased stent migration and even earlier stent occlusion with FCSEMS [59], while two other studies revealed no stent patency benefit between partially covered SEMS (PCSEMS) and UCSEMS [60,61]. Most studies to date on MDBO have shown no significant differences in stent patency between FCSEMS, PCSEMS, or UCSEMS. Notably, while FCSEMS is used by many well-recognized endoscopists, its superiority is still under debate.

Figure 2. Self-expanding metal stents for use in pancreatic cancers with malignant distal biliary obstruction.

Figure 3. Plastic stent for use in pancreatic cancers with malignant distal biliary obstruction.

4. Malignant Hilar Biliary Obstruction

EUS is a valuable diagnostic modality for the staging of hilum cholangiocarcinomas, particularly for the evaluation of unresectable perihilar cholangiocarcinoma for liver transplantation [62]. Percutaneous laparoscopic biopsy and even EUS-fine-needle aspiration (EUS-FNA) of the primary tumor are not recommended in patients who are candidates for liver transplantation because of the high risk of peritoneal dissemination following these procedures [63]. Endoscopic biliary stenting for malignant obstructive jaundice offers symptomatic improvements [64,65] and has been widely accepted as an effective palliation treatment [31,66], but no widespread consensus has yet been reached regarding the optimal stent types and placement procedures for stent insertion [67]. Liver
volume drainage in excess of 50% should be achieved using multiple stenting to improve survival [68]. Selection of the drainage method and stent requires the use of CT, MRI, or MRCP.

4.1. Bilateral or Unilateral Drainage

Some evidence indicates that in cases of bilateral biliary opacification, bilateral drainage offers a better survival benefit when compared to unilateral drainage [69,70]. After adjustment for the Bismuth stage, two parallel SEMS should be deployed for advanced cholangiocarcinomas such as Bismuth types III and IV obstructions [71]. PTCD is considered an alternative choice if primary endoscopic drainage fails, and some evidence has shown that PTCD is an even better choice for advanced hilum obstruction, which occurs in Bismuth types III and IV patients with unresectable malignant obstructions [71–74].

The evidence is still insufficient and no clear consensus has been reached regarding the benefits of unilateral versus bilateral drainage for hilar malignant obstruction, although the bilateral approach can be used by most experts using the SEMS stent-within-stent placement [75,76] with the newly designed Y-shaped devices, and this shows promising results [77,78]. These procedures can be performed using parallel [79] (Figure 4a) or stent-in-stent [80] (Figure 4b) deployment of SEMS, but not enough evidence is available to identify which method is preferable. Previous data have shown that draining 25% of the liver volume was sufficient to relieve jaundice [81]; however, a recent study indicated that patients who had liver volume drainage of >50% experienced greater jaundice relief than those who had a lower volume drained [68]. However, because the right lobe of the liver covers 55–60% of the liver volume, while the left and caudate lobes cover 30–35% and 10% of the liver volume, respectively [82], draining >50% of the liver volume usually requires the use of bilateral stenting or multi-segmental stenting, depending on the individual patient’s anatomy.

Figure 4. Parallel or stent-in-stent deployment of self-expanding metal stents for use in treatment of malignant hilar biliary obstruction (Courtesy of Dr. Nai-Jen Liu). (a) Parallel deployment; (b) stent-in-stent deployment

4.2. Stent Selection

Plastic stents and uncovered SEMS yield similar short-term outcomes in patients with malignant hilar strictures due to stent migration in SEMS [83]. SEMS provide a longer biliary patency when compared with plastic stents; thus, they are the choice of most endoscopists [64,69,74,84]. Covered
stents are not usually used in patients with malignant hilar biliary obstruction due to the possibility of unintentional obstruction of the contralateral and/or side branch ducts.

4.3. Rescue Management

EUS-guided biliary drainage via EUS-guided hepaticogastrostomy (EUS-HGS) is a good alternative for draining malignant hilar biliary obstruction following the failure of an initial ERCP. An EUS-guided rendezvous procedure with the conventional ERCP access [85,86] is typically used in most situations, except for concurrent duodenal obstruction. EUS-HGS [87,88] is the preferred treatment option if either a guidewire cannot pass through the duodenum or the presence of a concurrent duodenal obstruction is found. Another alternative approach to EUS-HGS is EUS-guided choledochoduodenostomy (EUS-CDS) [89], which offers management methods other than PTCD. Due to the high rate of complications, EUS-guided biliary drainage has served as an alternative approach over the last two years; however, some encouraging results have shown a similar safety profile and procedure success rate and even better stent patency during that same timeframe [36,37,90].

5. Summary

In cases of malignant biliary obstruction, CT, MRI, MRCP, and EUS should be used for tumor staging and further drainage planning. For resectable malignant biliary obstruction lesions, routine endoscopic drainage or ERCP are not advised, except in cases of concurrent infection. Endoscopic drainage is the treatment of choice for unresectable biliary obstructions. PTCD and EUS-guided biliary drainage can serve as alternative approach methods. EUS-guided biliary drainage can provide equal clinical benefits without increasing complications in a high-tech endoscopy center. In addition, PTCD plays an important role in community hospitals, where the ERCP and/or EUS approaches are not available.

For MDBO, single-stent insertion is adequate, and SEMS have better patency than plastic stents; however, the superiority of FCSEMS, PCSEMS, and UCSEMS remains under debate. For malignant hilar biliary obstructions, drainage of >50% of the liver volume should be achieved by either bilateral stenting or multi-segmental stenting, and SEMS' longer biliary patency when compared with plastic stents should be considered. The general approaches to malignant biliary obstruction are summarized in the flow chart presented in Figure 5.
Figure 5. Flow chart for the management of malignant biliary obstruction.

**Author Contributions:** C.-C.W. and M.-C.T. contributed to the conception and design; C.-C.W., W.-W.S., and T.-W.Y. contributed to the analysis and interpretation of previous literature; C.-C.W. and W.-W.S. contributed to drafting the manuscript; Yang TW and M.-C.T. contributed to critical revision of the manuscript; and M.-C.T. contributed to supervision.

**Funding:** Chung Shan Medical University Hospital research program, Taichung, Taiwan (CSH-2013-C-032).

**Conflicts of Interest:** The authors declare no conflicts of interest.

**Abbreviations**

ASGE: American Society for Gastrointestinal Endoscopy; CT: computed tomography; ECC: extrahepatic cholangiocarcinoma; ERCP: endoscopic retrograde cholangiopancreatography; EUS: endoscopic ultrasound sonography; EUS-FNA: endoscopic ultrasound sonography–fine-needle aspiration; EUS-BD: endoscopic ultrasound-guided biliary drainage; FCSEMS: fully covered self-expanding metal stent; ICC: intrahepatic cholangiocarcinoma; IDUS: intraductal ultrasound sonography; MDBO: malignant distal biliary obstruction; MRCP: magnetic resonance cholangiopancreatography; MRI: magnetic resonance imaging; PCSEMS: partially covered self-expanding metal stent; PS: plastic stent; PTCD: percutaneous trans-hepatic cholangiography and drainage; SEMS: self-expanding metal stent; UCSEMS: uncovered self-expanding metal stent.

**References**

1. Pinchuk, L.; Magnanini, F.; Nardi, G.; Bosolino, A.; Rubio, H. Percutaneous transhepatic biliary drainage in obstructive jaundice. *Acta Gastroenterol. Latinoam* 1981, **11**, 279–284.
2. Manegold, B.C. Obstructive jaundice of benign and malignant origin: Endoscopy in diagnosis and therapy. *Langenbecks Arch. Chir.* 1981, **355**, 263–271.
3. Safrany, L.; Schott, B.; Krause, S.; Balint, T.; Portocarrero, G. Endoscopic transpapillary bile duct drainage in malignant obstructive jaundice. *Dtsch. Med. Wochenschr.* 1982, 107, 1867–1871.

4. Roque, J.; Ho, S.H.; Goh, K.L. Preoperative drainage for malignant biliary strictures: Is it time for self-expanding metallic stents? *Clin. Endosc.* 2015, 48, 8–14.

5. Tyson, G.L.; Ilyas, J.A.; Duan, Z.; Green, L.K.; Younes, M.; El-Serag, H.B.; Davila, J.A. Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification. *Dig. Dis. Sci.* 2014, 59, 3103–3110.

6. Bertuccio, P.; Bosetti, C.; Levi, F.; Decarli, A.; Negri, E.; La Vecchia, C. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. *Ann. Oncol.* 2013, 24, 1667–1674.

7. Yadav, D.; Lowenfels, A.B. The epidemiology of pancreatitis and pancreatic cancer. *Gastroenterology* 2013, 144, 1252–1261.

8. Simile, M.M.; Bagella, P.; Vidili, G.; Spanu, A.; Manetti, R.; Sedaraiu, M.A.; Babudieri, S.; Madeddu, G.; Serra, P.A.; Altana, M.; et al. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials. *Medicina* 2019, 55, 42.

9. American Society for Gastrointestinal Endoscopy Standards of Practice Committee; Anderson, M.A.; Appalaneni, V.; Ben-Menachem, T.; Decker, G.A.; Early, D.S.; Evans, J.A.; Fanelli, R.D.; Fisher, D.A.; Fisher, L.R.; et al. The role of endoscopy in the evaluation and treatment of patients with biliary neoplasia. *Gastrointest. Endosc.* 2013, 77, 167–174.

10. De Angelis, C.; Marietti, M.; Bruno, M.; Pellicano, R.; Rizzetto, M. Endoscopic ultrasound in common bile duct dilatation with normal liver enzymes. *World J. Gastrointest. Endosc.* 2015, 7, 799–805.

11. Van der Gaag, N.A.; Rauws, E.A.; van Eijck, C.H.; Bruno, M.J.; van der Harst, E.; Kubben, F.J.; Gerritsen, J.J.; Greve, J.W.; Gerhards, M.F.; de Hingh, I.H.; et al. Preoperative biliary drainage for cancer of the head of the pancreas. *N. Engl. J. Med.* 2010, 362, 129–137.

12. Velanovich, V.; Kheibek, T.; Khan, M. Relationship of postoperative complications from preoperative biliary stents after pancreaticoduodenectomy. A new cohort analysis and meta-analysis of modern studies. *JOP 2009*, 10, 24–29.

13. Qiu, Y.D.; Bai, J.L.; Xu, F.G.; Ding, Y.T. Effect of preoperative biliary drainage on malignant obstructive jaundice: A meta-analysis. *World J. Gastroenterol.* 2011, 17, 391–396.

14. Sewnath, M.E.; Karsten, T.M.; Prins, M.H.; Rauws, E.J.; Obertop, H.; Gouma, D.J. A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice. *Ann. Surg.* 2002, 236, 17–27.

15. Bismuth, H.; Nakache, R.; Diamond, T. Management strategies in resection for hilar cholangiocarcinoma. *Ann. Surg.* 1992, 215, 31–38.

16. De Bellis, M.; Sherman, S.; Fogel, E.L.; Cramer, H.; Chappo, J.; McHenry, L., Jr.; Watkins, J.L.; Lehman, G.A. Tissue sampling at ERCP in suspected malignant biliary strictures (Part I). *Gastrointest. Endosc.* 2002, 56, 552–561.

17. Fogel, E.L.; deBellis, M.; McHenry, L.; Watkins, J.L.; Chappo, J.; Cramer, H.; Schmidt, S.; Lazzell-Pannell, L.; Sherman, S.; Lehman, G.A. Effectiveness of a new long cytology brush in the evaluation of malignant biliary obstruction: A prospective study. *Gastrointest. Endosc.* 2006, 63, 71–77.

18. Fukuda, Y.; Tsyuyuguchi, T.; Sakai, Y.; Tsuchiya, S.; Saisyo, H. Diagnostic utility of peroral cholangioscopy for various bile-duct lesions. *Gastrointest. Endosc.* 2005, 62, 374–382.

19. Shah, R.J.; Langer, D.A.; Antillon, M.R.; Chen, Y.K. Cholangioscopy and cholangioscopic forceps biopsy in patients with indeterminate pancreaticobiliary pathology. *Clin. Gastroenterol. Hepatol.* 2006, 4, 219–225.

20. Osanai, M.; Itoi, T.; Igarashi, Y.; Tanaka, K.; Kida, M.; Maguchi, H.; Yasuda, K.; Okano, N.; Imaiuzumi, H.; Itokawa, F. Peroral video cholangioscopy to evaluate indeterminate bile duct lesions and preoperative mucosal cancerous extension: A prospective multicenter study. *Endoscopy 2013*, 45, 635–642.

21. Navaneethan, U.; Hasan, M.K.; Lourduramy, V.; Njie, B.; Varadarajulu, S.; Hawes, R.H. Single-operator cholangioscopy and targeted biopsies in the diagnosis of indeterminate biliary strictures: A systematic review. *Gastrointest. Endosc.* 2015, 82, 608–614e602.

22. Zaydfudim, V.M.; Clark, C.J.; Kendrick, M.L.; Que, F.G.; Reid-Lombardo, K.M.; Donohue, J.H.; Farnell, M.B.; Nagorney, D.M. Correlation of staging systems to survival in patients with resected hilar cholangiocarcinoma. *Ann. J. Surg.* 2013, 206, 159–165.
43. Katsinelos, P.; Paikos, D.; Kountouras, J.; Chatzimavroudis, G.; Paroutoglou, G.; Moschos, I.; Gatopoulou, A.; Beltis, A.; Zavos, C.; Papaziogas, B. Tannenbaum and metal stents in the palliative treatment of malignant distal bile duct obstruction: A comparative study of patency and cost effectiveness. Surg. Endosc. 2006, 20, 1587–1593.

44. Soderlund, C.; Linder, S. Covered metal versus plastic stents for malignant common bile duct stenosis: A prospective, randomized, controlled trial. Gastrointest. Endosc. 2006, 63, 986–995.

45. Levy, M.J.; Baron, T.H.; Gostout, C.J.; Petersen, B.T.; Farnell, M.B. Palliation of malignant extrahepatic biliary obstruction with plastic versus expandable metal stents: An evidence-based approach. Clin. Gastroenterol. Hepatol. 2004, 2, 273–285.

46. Aadam, A.A.; Evans, D.B.; Khan, A.; Oh, Y.; Dua, K. Efficacy and safety of self-expandable metal stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: A prospective study. Gastrointest. Endosc. 2012, 76, 67–75.

47. Isayama, H.; Komatsu, Y.; Tsujino, T.; Sasahira, N.; Hirano, K.; Toda, N.; Nakai, Y.; Yamamoto, N.; Tada, M.; Yoshida, H.; et al. A prospective randomised study of “covered” versus “uncovered” diamond stents for the management of distal malignant biliary obstruction. Gut 2004, 53, 729–734.

48. Park, D.H.; Kim, M.H.; Choi, J.S.; Lee, S.S.; Seo, D.W.; Kim, J.H.; Han, J.; Kim, J.C.; Choi, E.K.; Lee, S.K. Covered versus uncovered wallstent for malignant extrahepatic biliary obstruction: A cohort comparative analysis. Clin. Gastroenterol. Hepatol. 2006, 4, 790–796.

49. Yoon, W.J.; Lee, J.K.; Lee, K.H.; Lee, W.J.; Ryu, J.K.; Kim, Y.T.; Yoon, Y.B. A comparison of covered and uncovered Wallstents for the management of distal malignant biliary obstruction. Gastrointest. Endosc. 2006, 63, 996–1000.

50. Fumex, F.; Coumaros, D.; Napoleon, B.; Barthet, M.; Laugier, R.; Yzet, T.; Le Sidaner, A.; Desurmont, P.; Lamouliatte, H.; Letard, J.C.; et al. Similar performance but higher cholecystitis rate with covered biliary stents: Results from a prospective multicenter evaluation. Endoscopy 2006, 38, 787–792.

51. Petersen, B.T.; Kahaleh, M.; Kozarek, R.A.; Loren, D.; Gupta, K.; Kowalski, T.; Freeman, M.; Chen, Y.K.; Branch, M.S.; Edmundowicz, S.; et al. A multicenter, prospective study of a new fully covered expandable metal biliary stent for the palliative treatment of malignant bile duct obstruction. Gastroenterol. Res. Pract. 2013, 2013, 642428.

52. Kitano, M.; Yamashita, Y.; Tanaka, K.; Konishi, H.; Yazumi, S.; Nakai, Y.; Nishiyama, O.; Uehara, H.; Mitoro, A.; Sanuki, T.; et al. Covered self-expandable metal stents with an anti-migration system improve patency duration without increased complications compared with uncovered stents for distal biliary obstruction caused by pancreatic carcinoma: A randomized multicenter trial. Am. J. Gastroenterol. 2013, 108, 1713–1722.

53. Yokota, Y.; Fukasawa, M.; Takano, S.; Kadokura, M.; Shindo, H.; Takahashi, E.; Hirose, S.; Kawakami, S.; Fukasawa, Y.; Sato, T.; et al. Partially covered metal stents have longer patency than uncovered and fully covered metal stents in the management of distal malignant biliary obstruction: A retrospective study. BMC Gastroenterol. 2017, 17, 105.

54. Kahaleh, M.; Talreja, J.P.; Loren, D.E.; Kowalski, T.E.; Poneros, J.M.; Degaetani, M.; Rajiman, I.; Seipal, D.V.; Patel, S.; Rosenkranz, L.; et al. Evaluation of a fully covered self-expanding metal stent with flared ends in malignant biliary obstruction: A multicenter study. J. Gastroenterol. 2013, 47, e96–e100.

55. Lee, B.S.; Ryu, J.K.; Jang, D.K.; Chung, K.H.; Yoon, W.J.; Kim, J.; Woo, S.M.; Lee, S.H.; Lee, W.J.; Kim, Y.T. Reintervention for occluded metal stent in malignant bile duct obstruction: A prospective randomized trial comparing covered and uncovered metal stent. J. Gastroenterol. Hepatol. 2016, 31, 1901–1907.

56. Lee, J.H.; Krishna, S.G.; Singh, A.; Ladha, H.S.; Slack, R.S.; Ramireddy, S.; Raju, G.S.; Davila, M.; Ross, W.A. Comparison of the utility of covered metal stents versus uncovered metal stents in the management of malignant biliary strictures in 749 patients. Gastrointest. Endosc. 2013, 78, 312–324.

57. Li, J.; Li, T.; Sun, P.; Yu, Q.; Wang, K.; Chang, W.; Song, Z.; Zheng, Q. Covered versus Uncovered Self-Expandable Metal Stents for Managing Malignant Biliary Obstruction: A Meta-Analysis. PLoS ONE 2016, 11, e0149066.

58. Almadi, M.A.; Barkun, A.N.; Martel, M. No benefit of covered vs. uncovered self-expandable metal stents in patients with malignant distal biliary obstruction: A meta-analysis. Clin. Gastroenterol. Hepatol. 2013, 11, 27–37 e21.

59. Conio, M.; Mangiavillano, B.; Caruso, A.; Filiberti, R.A.; Baron, T.H.; De Luca, L.; Signorelli, S.; Crespi, M.; Marini, M.; Ravelli, P.; et al. Covered versus uncovered self-expandable metal stent for palliation of primary
malignant extrahepatic biliary strictures: A randomized multicenter study. Gastrointest. Endosc. 2018, 88, 283–291 e283.
60. Kim, J.Y.; Ko, G.B.; Lee, T.H.; Park, S.H.; Lee, Y.N.; Cho, Y.S.; Jung, Y.; Chung, I.K.; Choi, H.J.; Cha, S.W.; et al. Partially Covered Metal Stents May Not Prolong Stent Patency Compared to Uncovered Stents in Unresectable Malignant Distal Biliary Obstruction. Gut Liver 2017, 11, 440–446.
61. Yang, M.J.; Kim, J.H.; Yoo, B.M.; Hwang, J.C.; Yoo, J.H.; Lee, K.S.; Kang, J.K.; Kim, S.S.; Lim, S.G.; Shin, S.J.; et al. Partially covered versus uncovered self-expandable nitinol stents with anti-migration properties for the palliation of malignant distal biliary obstruction: A randomized controlled trial. Scand. J. Gastroenterol. 2015, 50, 1490–1499.
62. Levy, M.J.; Heimbach, J.K.; Gores, G.J. Endoscopic ultrasound staging of cholangiocarcinoma. Curr. Opin. Gastroenterol. 2012, 28, 244–252.
63. Heimbach, J.K.; Sanchez, W.; Rosen, C.B.; Gores, G.J. Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB 2011, 13, 356–360.
64. Rerknimitr, R.; Angsuwatharakon, P.; Ratanachu-ek, T.; Khor, C.J.; Ponrudurai, R.; Moon, J.H.; See, D.W.; Pantongrag-Brown, L.; Sangchan, A.; Pisespongpa, P.; et al. Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma. J. Gastroenterol. Hepatol. 2013, 28, 593–607.
65. Saluja, S.S.; Gulati, M.; Garg, P.K.; Pal, H.; Pal, S.; Sahni, P.; Chattopadhyay, T.K. Endoscopic or percutaneous biliary drainage for gallbladder cancer: A randomized trial and quality of life assessment. Clin. Gastroenterol. Hepatol. 2008, 6, 944–950 e943.
66. Bueno, J.T.; Gerdes, H.; Kurtz, R.C. Endoscopic management of occluded biliary Wallstents: A cancer center experience. Gastrointest. Endosc. 2003, 58, 879–884.
67. Katanuma, A.; Irisawa, A.; Itoi, T. Otaru consensus on biliary stenting for unresectable malignant hilar biliary obstruction. Dig. Endosc. 2013, 25 (Suppl. 2), 58–62.
68. Vienne, A.; Hobeika, E.; Gouya, H.; Lapidus, N.; Fritsch, J.; Choury, A.D.; Chryssostalis, A.; Gaudric, M.; Pelletier, G.; Buffet, C.; et al. Prediction of drainage effectiveness during endoscopic stenting of malignant hilar strictures: The role of liver volume assessment. Gastrointest. Endosc. 2010, 72, 728–735.
69. Perdue, D.G.; Freeman, M.L.; DiSario, J.A.; Nelson, D.B.; Fennerty, M.B.; Lee, J.G.; Overby, C.S.; Ryan, M.E.; Bochna, G.S.; Snady, H.W.; et al. Plastic versus self-expanding metallic stents for malignant hilar biliary obstruction: A prospective multicenter observational cohort study. J. Clin. Gastroenterol. 2008, 42, 1040–1046.
70. Deviere, J.; Baize, M.; de Toeufl, J.; Cremer, M. Long-term follow-up of patients with hilar malignant stricture treated by endoscopic internal biliary drainage. Gastrointest. Endosc. 1998, 34, 95–101.
71. Inal, M.; Akgul, E.; Aksungur, E.; Seydaoglu, G. Percutaneous placement of biliary metallic stents in patients with malignant hilar obstruction: Unilobar versus bilobar drainage. J. Vasc. Interv. Radiol. 2003, 14, 1409–1416.
72. Lee, S.H.; Park, J.K.; Yoon, W.J.; Lee, J.K.; Ryu, J.K.; Yoon, Y.B.; Kim, Y.T. Optimal biliary drainage for inoperable Klatskin’s tumor based on Bismuth type. World J. Gastroenterol. 2007, 13, 3948–3955.
73. Rerknimitr, R.; Kladcharoen, N.; Mahachai, V.; Kullavanijaya, P. Result of endoscopic biliary drainage in hilar cholangiocarcinoma. J. Clin. Gastroenterol. 2004, 38, 518–523.
74. Paik, W.H.; Park, Y.S.; Hwang, J.H.; Lee, S.H.; Yoon, C.J.; Kang, S.G.; Lee, J.K.; Ryu, J.K.; Kim, Y.T.; Yoon, Y.B. Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: A percutaneous versus endoscopic approach. Gastrointest. Endosc. 2009, 69, 55–62.
75. Chahal, P.; Baron, T.H. Expandable metal stents for endoscopic bilateral stent-within-stent placement for malignant hilar biliary obstruction. Gastrointest. Endosc. 2010, 71, 195–199.
76. Kogure, H.; Isayama, H.; Kawakubo, K.; Sasaki, T.; Yamamoto, N.; Hirano, K.; Sasahira, N.; Tsujino, T.; Tada, M.; Koike, K. Endoscopic bilateral metallic stenting for malignant hilar obstruction using newly designed stents. J. Hepatobiliary Pancreat. Sci. 2011, 18, 653–657.
77. Hwang, J.C.; Kim, J.H.; Lim, S.G.; Kim, S.S.; Yoo, B.M.; Cho, S.W. Y-shaped endoscopic bilateral metal stent placement for malignant hilar biliary obstruction: Prospective long-term study. Scand. J. Gastroenterol. 2011, 46, 326–332.
78. Kogure, H.; Isayama, H.; Nakai, Y.; Tsujino, T.; Ito, Y.; Yamamoto, K.; Mizuno, S.; Yagioka, H.; Kawakubo, K.; Sasaki, T.; et al. Newly designed large cell Niti-S stent for malignant hilar biliary obstruction: A pilot study. Surg. Endosc. 2011, 25, 463–467.
79. Saleem, A.; Baron, T.H.; Gostout, C.J. Large-diameter therapeutic channel duodenoscope to facilitate simultaneous deployment of side-by-side self-expandable metal stents in hilar cholangiocarcinoma. *Gastrointest. Endosc.* 2010, 72, 628–631.

80. Park, D.H.; Lee, S.S.; Moon, J.H.; Choi, H.J.; Cha, S.W.; Kim, J.H.; Seo, D.W.; Lee, S.K.; Park, S.H.; Lee, M.S.; et al. Newly designed stent for endoscopic bilateral stent-in-stent placement of metallic stents in patients with malignant hilar biliary strictures: Multicenter prospective feasibility study (with videos). *Gastrointest. Endosc.* 2009, 69, 1357–1360.

81. Dowsett, J.F.; Vaira, D.; Hatfield, A.R.; Cairns, S.R.; Polydorou, A.; Frost, R.; Croker, J.; Cotton, P.B.; Russell, R.C.; Mason, R.R. Endoscopic biliary therapy using the combined percutaneous and endoscopic technique. *Gastroenterology* 1989, 96, 1180–1186.

82. Bismuth, H. Surgical anatomy and anatomical surgery of the liver. *World J. Surg.* 1982, 6, 3–9.

83. Moy, B.T.; Birk, J.W. An Update to Hepatobiliary Stents. *J. Clin. Transl. Hepatol.* 2015, 3, 67–77.

84. Wagner, H.J.; Knym, K.; Valkil, N.; Klose, K.J. Plastic endoprostheses versus metal stents in the palliative treatment of malignant hilar biliary obstruction. A prospective and randomized trial. *Endoscopy* 1993, 25, 213–218.

85. Kim, Y.S.; Gupta, K.; Mallory, S.; Li, R.; Kinney, T.; Freeman, M.L. Endoscopic ultrasound rendezvous for bile duct access using a transduodenal approach: Cumulative experience at a single center. A case series. *Endoscopy* 2010, 42, 496–502.

86. Dhir, V.; Bhandari, S.; Bapat, M.; Maydeo, A. Comparison of EUS-guided rendezvous and precut papillotomy techniques for biliary access (with videos). *Gastrointest. Endosc.* 2012, 75, 354–359.

87. Will, U.; Thiene, A.; Fueldner, F.; Gerlach, R.; Wanzar, I.; Meyer, F. Treatment of biliary obstruction in selected patients by endoscopic ultrasonography (EUS)-guided transluminal biliary drainage. *Endoscopy* 2007, 39, 292–295.

88. Park, D.H.; Song, T.J.; Eum, J.; Moon, S.H.; Lee, S.S.; Seo, D.W.; Lee, S.K.; Kim, M.H. EUS-guided hepatigastrostomy with a fully covered metal stent as the biliary diversion technique for an occluded biliary metal stent after a failed ERCP (with videos). *Gastrointest. Endosc.* 2010, 71, 413–419.

89. Komaki, T.; Kitano, M.; Sakamoto, H.; Kudo, M. Endoscopic ultrasonography-guided biliary drainage: Evaluation of a choledochoduodenostomy technique. *Pancreatology* 2011, 11 (Suppl. 2), 47–51.

90. Dhir, V.; Itoi, T.; Khashab, M.A.; Park, D.H.; Yuen Bun Teoh, A.; Attam, R.; Messallam, A.; Varadarajulu, S.; Maydeo, A. Multicenter comparative evaluation of endoscopic placement of expandable metal stents for malignant distal common bile duct obstruction by ERCP or EUS-guided approach. *Gastrointest. Endosc.* 2015, 81, 913–923.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).